Respiratory Drugs Pipeline Analysis
Overview: Pulmonary medicine is the branch of medical science that deals with diagnosis, prevention, and treatment of diseases affecting the respiratory system. Respiratory drugs finds its applications in Asthma, COPD, Cystic Fibrosis, Allergic Rhinitis and Others. Asthma is the major market share holder currently. The intensity of competition in the respiratory drug market is high with few players dominating the market. The high investments made in the development of respiratory drug delivery systems have favored the growth of the market. The entry of innovative and effective drugs in the market is expected to drive the future of the market.
Short-Acting Beta2-Agonists (SABA), Inhaled corticosteroids (ICS), anticholinergics, long-acting beta2-agonists (LABA), antihistamines, vasodilators, combination drugs, and others are the major respiratory dugs classes available in the market. Currently, primarily combination drugs drive the market, with top brands facing no real competition from generic alternatives. The emergence of inexpensive, state-of-the-art and effective drug delivery devices will provide stimulate the market growth.
Industry Trends
More than 30 companies pipeline for the respiratory drugs is analyzed in the study. GlaxoSmithKline plc has the highest number of pipeline molecules in various clinical trials phases.
Benefits: The report provides complete details about the usage and adoption rate of respiratory drugs in various regions. With that, key stakeholders can know about the major trends, drivers, investments, and vertical player’s initiatives. Moreover, the report provides details about the major challenges that are going to impact on the market growth. Additionally, the report gives the complete details about the key business opportunities to key stakeholders to expand their business and capture the revenue in the specific verticals to analyze before investing or expanding the business in this market.